Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230016/S003

MAGE-A4 IHC 1F9 pharmDx

Agilent Technologies, Inc. · Decision date Sep 15, 2026

FDA DECISIONP230016/S003

What did the FDA approve?

FDA records P230016/S003 as a supplement to PMA P230016, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Sep 15, 2026.

FDA approval order statement

MAGE-A4 IHC IF9 pharmDx is a qualitative immunohistochemical (IHC) assay using monoclonal mouse anti-MAGE-A4, Clone OTI1F9, intended for use in the detection of MAGE-A4 protein in formalin-fixed, paraffin-embedded (FFPE) synovial sarcoma tissue using the EnVision FLEX visualization system on Autostainer Link 48. MAGE-A4 protein expression in synovial sarcoma is determined by using the MAGE-A4 Tumor Intensity Proportion Score (TIPS), which is the overall percentage of viable tumor cells showing MAGE-A4 nuclear and/or cytoplasmic staining at staining intensity = 2+. The specimen should be considered positive if MAGE-A4 TIPS (= 2+) is = 75%.MAGE-A4 IHC 1F9 pharmDx is indicated as an aid in identifying patients with synovial sarcoma for whom TECELRA (afamitresgene autoleucel), a MAGE-A4-directed genetically modified autologous T-cell immunotherapy, is being considered.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Pathology
Decision date
Sep 15, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P230016/S003
Regulatory pathway
PMA supplement
Product code
SBL
Decision code
APPR
Decision date
Sep 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry Assay, Antibody, Melanoma-associated antigen A4.

Product code
SBL
FDA device class
3

For the original device and its historical approval scope, see PMA P230016. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230016 · Original PMA

    MAGE-A4 IHC 1F9 pharmDx

  2. P230016/S003 received

    Application receipt date recorded by FDA.

  3. P230016/S005 · Related supplement

    MAGE-A4 IHC 1F9 pharmDx

  4. P230016/S003 · FDA decision

    Normal 180 Day Track

  5. P230016/S004 · Related supplement

    MAGE-A4 IHC 1F9 pharmDx

Timeline entries are records held by MedtechLedger for P230016. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230016

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA approvalAug 1, 2024FDA
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 21, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6392 Via Real, Carpinteria, CA, 93013

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records